Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Tex.
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Tex.
J Thorac Cardiovasc Surg. 2019 Oct;158(4):1234-1241.e16. doi: 10.1016/j.jtcvs.2019.02.133. Epub 2019 May 11.
Several options are available for the local treatment of colorectal pulmonary metastases; however, the efficacy of each treatment has not been well characterized. We compared the risk of local recurrence after wedge resection or stereotactic body radiation therapy for pulmonary metastases of colorectal origin.
We retrospectively reviewed records of patients treated for pulmonary colorectal metastases with stereotactic body radiation therapy or wedge resection from 2006 to 2016 at a single institution. Local recurrence was defined as an enlarging nodule either adjacent to the staple line or within the radiation field on computed tomography. Matching weights using the propensity score with death as a competing event was used to estimate the risk of local recurrence for each metastatic nodule.
A total of 381 patients underwent 762 wedge resections and 64 courses of stereotactic body radiation therapy for definitive treatment of 826 pulmonary nodules. The risk of local recurrence was increased with stereotactic body radiation therapy (hazard ratio, 3.28; 95% confidence interval, 1.53-7.04; P = .002) and larger tumor size (hazard ratio, 1.38 per additional centimeter; 95% confidence interval, 1.01-1.87; P = .042). After reweighting with matching weights, the marginal 2-year risk of local recurrence for each nodule was 14.1% (95% confidence interval, 9.8-18.5) after wedge resection and 29.4% (95% confidence interval, 13.8-45.0) after stereotactic body radiation therapy (P = .023).
Pulmonary colorectal metastases treated with stereotactic body radiation therapy have a higher risk of local recurrence than those treated with wedge resection. Stereotactic body radiation therapy should be reserved for patients with comorbidities precluding surgical resection.
对于结直肠肺转移瘤的局部治疗有多种选择,但每种治疗方法的疗效尚未得到很好的描述。我们比较了楔形切除术或立体定向体部放射治疗结直肠来源肺转移瘤后局部复发的风险。
我们回顾性地分析了 2006 年至 2016 年在一家医疗机构接受立体定向体部放射治疗或楔形切除术治疗肺结直肠转移瘤的患者记录。局部复发定义为 CT 上毗邻吻合钉线或放射野内的增大结节。使用倾向评分匹配死亡作为竞争事件来匹配权重,以估计每个转移灶的局部复发风险。
共 381 例患者接受了 762 次楔形切除术和 64 次立体定向体部放射治疗,以明确治疗 826 个肺结节。立体定向体部放射治疗(风险比,3.28;95%置信区间,1.53-7.04;P=0.002)和肿瘤较大(风险比,每增加 1 厘米增加 1.38;95%置信区间,1.01-1.87;P=0.042)与局部复发风险增加相关。通过匹配权重重新加权后,每个结节的 2 年边缘局部复发率分别为楔形切除术组 14.1%(95%置信区间,9.8-18.5)和立体定向体部放射治疗组 29.4%(95%置信区间,13.8-45.0)(P=0.023)。
与楔形切除术相比,立体定向体部放射治疗的结直肠肺转移瘤局部复发风险更高。立体定向体部放射治疗应保留给不能手术切除的合并症患者。